Obesity and Alzheimer’s drugs pack one-two punch to power Eli Lilly higher in 2024

Eli Lilly & Co. Mounjaro brand tirzepatide medication arranged at a pharmacy in Provo, Utah, US, on Monday, Nov. 27, 2023. 

George Frey | Bloomberg | Getty Images

Investor optimism for Eli Lilly‘s diabetes and obesity treatments in 2023 lifted the stock to its seventh annual gain in a row. In the new year, it should be the same old story.

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *